List view / Grid view
The researchers explored the possibility of using the probiotic bacteria Lactobacillus reuteri as a novel oral drug delivery platform to treat rheumatoid arthritis in an animal model.
What is multiplexed immunofluorescence microscopy imaging?
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.
The scientists argue the technique enables the creation of complex, data-rich “maps” of organs, including diseased organs and tumours, which could be widely useful in pre-clinical research.
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.
The scientists discovered that dual knockout of genes in organoids grown from human tissue can generate a model of a potential therapeutic target for gastroesophageal junction cancer.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
The scientists hope the human body plan will increase the understanding of the aetiology and pathology of disease.
Researchers have genetically profiled nearly 200,000 cells from lungs, mapping their precise locations in tissue to discover an unexpected new immune niche in our airways.
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
This exclusive interview highlights some of Dr Arthur Suckow’s insights into how his team uses RNA therapies to treat rare diseases such as Charcot-Marie-Tooth 1A.
Join Malvern Panalytical for a 15-minute webinar to learn about ex vivo inflammasome slice assays for neuroinflammation discovery.
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
Scottish researchers uncovered that drugs used to treat angina and high blood pressure, could be used to treat AKI.
